TKIs used for the treatment of Ph + leukemia such as dasatinib are dual ABL1/SFK inhibitors that combine in one compound the inhibition of two kinases shown to be indispensable for the growth of FKH1 cells. The gene discussed is ABL1; the disease is leukemia.